| Year |
Citation |
Score |
| 2023 |
Batra J, Panchadsaram J, Tevz G, Fernando A, Malik A, Rockstroh A, Kryza T, Walpole C, Moya L, Lehman M, Nelson C, BioResource TAPC, Consortium TP, Sriniva S, Clements J. Unravelling the Role of Iroquois Homeobox 4 and its Interplay with Androgen Receptor in Prostate Cancer. Research Square. PMID 38076926 DOI: 10.21203/rs.3.rs-3295914/v1 |
0.499 |
|
| 2023 |
Thomas PB, Alinezhad S, Joshi A, Sweeney K, Tse BWC, Tevz G, McPherson S, Nelson CC, Williams ED, Vela I. Introduction of Androgen Receptor Targeting shRNA Inhibits Tumor Growth in Patient-Derived Prostate Cancer Xenografts. Current Oncology (Toronto, Ont.). 30: 9437-9447. PMID 37999103 DOI: 10.3390/curroncol30110683 |
0.497 |
|
| 2023 |
Adams MN, Croft LV, Urquhart A, Saleem MAM, Rockstroh A, Duijf PHG, Thomas PB, Ferguson GP, Najib IM, Shah ET, Bolderson E, Nagaraj S, Williams ED, Nelson CC, O'Byrne KJ, et al. hSSB1 (NABP2/OBFC2B) modulates the DNA damage and androgen-induced transcriptional response in prostate cancer. The Prostate. PMID 36811381 DOI: 10.1002/pros.24496 |
0.435 |
|
| 2022 |
Chawla S, Rockstroh A, Lehman M, Ratther E, Jain A, Anand A, Gupta A, Bhattacharya N, Poonia S, Rai P, Das N, Majumdar A, Ahuja G, Hollier BG, Nelson CC, et al. Gene expression based inference of cancer drug sensitivity. Nature Communications. 13: 5680. PMID 36167836 DOI: 10.1038/s41467-022-33291-z |
0.345 |
|
| 2021 |
Bock N, Kryza T, Shokoohmand A, Röhl J, Ravichandran A, Wille ML, Nelson CC, Hutmacher DW, Clements JA. In vitro engineering of a bone metastases model allows for study of the effects of antiandrogen therapies in advanced prostate cancer. Science Advances. 7. PMID 34193425 DOI: 10.1126/sciadv.abg2564 |
0.412 |
|
| 2021 |
Philp LK, Rockstroh A, Sadowski MC, Taherian Fard A, Lehman M, Tevz G, Libério MS, Bidgood CL, Gunter JH, McPherson S, Bartonicek N, Wade JD, Otvos L, Nelson CC. Leptin antagonism inhibits prostate cancer xenograft growth and progression. Endocrine-Related Cancer. PMID 33794502 DOI: 10.1530/ERC-20-0405 |
0.445 |
|
| 2021 |
Thomas PB, Jeffery P, Gahete MD, Whiteside E, Walpole C, Maugham M, Jovanovic L, Gunter J, Williams E, Nelson C, Herington A, Luque RM, Veedu R, Chopin LK, Seim I. The long non-coding RNA GHSROS reprograms prostate cancer cell lines toward a more aggressive phenotype. Peerj. 9: e10280. PMID 33585078 DOI: 10.7717/peerj.10280 |
0.535 |
|
| 2020 |
Philp LK, Rockstroh A, Lehman M, Sadowski MC, Bartonicek N, Wade JD, Otvos L, Nelson CC. Adiponectin receptor activation inhibits prostate cancer xenograft growth. Endocrine-Related Cancer. PMID 33112829 DOI: 10.1530/ERC-20-0297 |
0.429 |
|
| 2020 |
Kumar R, Bidgood CL, Levrier C, Gunter JH, Nelson CC, Sadowski MC, Davis RA. Synthesis of a Unique Psammaplysin F Library and Functional Evaluation in Prostate Cancer Cells by Multiparametric Quantitative Single Cell Imaging. Journal of Natural Products. PMID 32691595 DOI: 10.1021/acs.jnatprod.0c00121 |
0.304 |
|
| 2020 |
Tousignant KD, Rockstroh A, Poad BLJ, Talebi A, Young RSE, Taherian Fard A, Gupta R, Zang T, Wang C, Lehman ML, Swinnen JV, Blanksby SJ, Nelson CC, Sadowski MC. Therapy-induced lipid uptake and remodeling underpin ferroptosis hypersensitivity in prostate cancer. Cancer & Metabolism. 8: 11. PMID 32577235 DOI: 10.1186/s40170-020-00217-6 |
0.318 |
|
| 2020 |
Yeh MC, Tse BWC, Fletcher NL, Houston ZH, Lund M, Volpert M, Stewart C, Sokolowski KA, Jeet V, Thurecht KJ, Campbell DH, Walsh BJ, Nelson CC, Russell PJ. Targeted beta therapy of prostate cancer with Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1). Ejnmmi Research. 10: 46. PMID 32382920 DOI: 10.1186/s13550-020-00637-x |
0.383 |
|
| 2020 |
Nouri M, Massah S, Caradec J, Lubik AA, Li N, Truong S, Lee AR, Fazli L, Ramnarine VR, Lovnicki JM, Moore J, Wang M, Foo J, Gleave ME, Hollier BG, ... Nelson CC, et al. Transient Sox9 Expression Facilitates Progression to Castrate Resistant Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31919137 DOI: 10.1158/1078-0432.CCR-19-0098 |
0.468 |
|
| 2019 |
Kryza T, Bock N, Lovell S, Rockstroh A, Lehman ML, Lesner A, Panchadsaram J, Silva LM, Srinivasan S, Snell CE, Williams ED, Fazli L, Gleave M, Batra J, Nelson C, et al. The molecular function of kallikrein-related peptidase 14 demonstrates a key modulatory role in advanced prostate cancer. Molecular Oncology. PMID 31630475 DOI: 10.1002/1878-0261.12587 |
0.561 |
|
| 2019 |
Sarkar PL, Lee W, Williams ED, Lubik AA, Stylianou N, Shokoohmand A, Lehman ML, Hollier BG, Gunter JH, Nelson CC. Insulin Enhances Migration and Invasion in Prostate Cancer Cells by Up-Regulation of FOXC2. Frontiers in Endocrinology. 10: 481. PMID 31379747 DOI: 10.3389/fendo.2019.00481 |
0.383 |
|
| 2019 |
Bock N, Shokoohmand A, Kryza T, Röhl J, Meijer J, Tran PA, Nelson CC, Clements JA, Hutmacher DW. Engineering osteoblastic metastases to delineate the adaptive response of androgen-deprived prostate cancer in the bone metastatic microenvironment. Bone Research. 7: 13. PMID 31044095 DOI: 10.1038/s41413-019-0049-8 |
0.365 |
|
| 2019 |
Tousignant KD, Rockstroh A, Taherian Fard A, Lehman ML, Wang C, McPherson SJ, Philp LK, Bartonicek N, Dinger ME, Nelson CC, Sadowski MC. Lipid uptake is an androgen-enhanced lipid supply pathway associated with prostate cancer disease progression and bone metastasis. Molecular Cancer Research : McR. PMID 30808729 DOI: 10.1158/1541-7786.MCR-18-1147 |
0.462 |
|
| 2018 |
Maugham ML, Seim I, Thomas PB, Crisp GJ, Shah ET, Herington AC, Gregory LS, Nelson CC, Jeffery PL, Chopin LK. Limited short-term effects on human prostate cancer xenograft growth and epidermal growth factor receptor gene expression by the ghrelin receptor antagonist [D-Lys]-GHRP-6. Endocrine. PMID 30390209 DOI: 10.1007/s12020-018-1796-9 |
0.457 |
|
| 2018 |
Stylianou N, Lehman ML, Wang C, Fard AT, Rockstroh A, Fazli L, Jovanovic L, Ward M, Sadowski MC, Kashyap AS, Buttyan R, Gleave ME, Westbrook TF, Williams ED, Gunter JH, ... Nelson CC, et al. A molecular portrait of epithelial-mesenchymal plasticity in prostate cancer associated with clinical outcome. Oncogene. PMID 30194451 DOI: 10.1038/S41388-018-0488-5 |
0.399 |
|
| 2018 |
Egbewande FA, Sadowski MC, Levrier C, Tousignant KD, White JM, Coster MJ, Nelson CC, Davis RA. Identification of Gibberellic Acid Derivatives That Deregulate Cholesterol Metabolism in Prostate Cancer Cells. Journal of Natural Products. PMID 29474071 DOI: 10.1021/acs.jnatprod.7b00929 |
0.355 |
|
| 2017 |
Lai J, Moya L, An J, Hoffman A, Srinivasan S, Panchadsaram J, Walpole C, Perry-Keene JL, Chambers S, Lehman ML, Nelson CC, Clements JA, Batra J. A microsatellite repeat in PCA3 long non-coding RNA is associated with prostate cancer risk and aggressiveness. Scientific Reports. 7: 16862. PMID 29203868 DOI: 10.1038/s41598-017-16700-y |
0.496 |
|
| 2017 |
Soekmadji C, Rockstroh A, Ramm GA, Nelson CC, Russell PJ. Extracellular Vesicles in the Adaptive Process of Prostate Cancer During Inhibition of Androgen Receptor Signalling by Enzalutamide. Proteomics. PMID 29105980 DOI: 10.1002/pmic.201600427 |
0.471 |
|
| 2017 |
Soekmadji C, Riches JD, Russell PJ, Ruelcke JE, McPherson S, Wang C, Hovens CM, Corcoran NM, Hill MM, Nelson CC. Modulation of paracrine signaling by CD9 positive small extracellular vesicles mediates cellular growth of androgen deprived prostate cancer. Oncotarget. 8: 52237-52255. PMID 28881726 DOI: 10.18632/oncotarget.11111 |
0.382 |
|
| 2017 |
Soekmadji C, Corcoran NM, Oleinikova I, Jovanovic L, Ramm GA, Nelson CC, Jenster G, Russell PJ. Extracellular vesicles for personalized therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer. The Prostate. PMID 28856701 DOI: 10.1002/pros.23403 |
0.426 |
|
| 2017 |
Levrier C, Rockstroh A, Gabrielli B, Kavallaris M, Lehman M, Davis RA, Sadowski MC, Nelson CC. Discovery of Thalicthuberine as a Novel Antimitotic Agent from Nature that Disrupts Microtubule Dynamics and Induces Apoptosis in Prostate Cancer Cells. Cell Cycle (Georgetown, Tex.). 0. PMID 28749250 DOI: 10.1080/15384101.2017.1356512 |
0.324 |
|
| 2017 |
Seim I, Jeffery PL, Thomas PB, Nelson CC, Chopin LK. Whole-Genome Sequence of the Metastatic PC3 and LNCaP Human Prostate Cancer Cell Lines. G3 (Bethesda, Md.). PMID 28413162 DOI: 10.1534/g3.117.039909 |
0.432 |
|
| 2017 |
Kulasinghe A, Tran TH, Blick T, O'Byrne K, Thompson EW, Warkiani ME, Nelson C, Kenny L, Punyadeera C. Enrichment of circulating head and neck tumour cells using spiral microfluidic technology. Scientific Reports. 7: 42517. PMID 28198401 DOI: 10.1038/Srep42517 |
0.332 |
|
| 2017 |
Nouri M, Caradec J, Lubik AA, Li N, Hollier BG, Takhar M, Altimirano-Dimas M, Chen M, Roshan-Moniri M, Butler M, Lehman M, Bishop J, Truong S, Huang SC, Cochrane D, ... ... Nelson C, et al. Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance. Oncotarget. PMID 28145883 DOI: 10.18632/Oncotarget.14850 |
0.523 |
|
| 2017 |
Tse BW, Volpert M, Ratther E, Stylianou N, Nouri M, McGowan K, Lehman ML, McPherson SJ, Roshan-Moniri M, Butler MS, Caradec J, Gregory-Evans CY, McGovern J, Das R, Takhar M, ... ... Nelson CC, et al. Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality. Oncogene. PMID 28092670 DOI: 10.1038/Onc.2016.482 |
0.499 |
|
| 2017 |
Volpert M, Tse B, Ratther E, Stylianou N, Nouri M, Lehman M, McPherson S, Roshan-Moniri M, Takhar M, Erho N, Alshalafa M, Davicioni E, Jenkins R, Ross A, Karnes J, ... ... Nelson C, et al. Abstract 4908: Neuropilin-1 is up-regulated in the adaptive response of prostate tumors to androgen targeted therapies and is prognostic of metastatic progression and patient mortality Cancer Research. 77: 4908-4908. DOI: 10.1158/1538-7445.Am2017-4908 |
0.56 |
|
| 2017 |
Joshi A, Nicholson C, Rhee H, Hutchinson A, McPherson S, Gunter J, Williams E, Nelson C, Vela I. PNFBA-08 NOVEL
IN VITRO
ORGANOID TECHNOLOGY TO FACILITATE A PRECISION MEDICINE APPROACH IN THE MANAGEMENT OF MEN WITH BIOCHEMICAL RECURRENCE OF PROSTATE CANCER Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.3237 |
0.507 |
|
| 2016 |
Levrier C, Sadowski MC, Rockstroh A, Gabrielli B, Kavallaris M, Lehman M, Davis RA, Nelson CC. 6α-Acetoxyanopterine: A Novel Structure Class of Mitotic Inhibitor Disrupting Microtubule Dynamics in Prostate Cancer Cells. Molecular Cancer Therapeutics. PMID 27760837 DOI: 10.1158/1535-7163.MCT-16-0325 |
0.408 |
|
| 2016 |
Kulasinghe A, Kenny L, Perry C, Thiery JP, Jovanovic L, Vela I, Nelson C, Punyadeera C. Impact of label-free technologies in head and neck cancer circulating tumour cells. Oncotarget. PMID 27655722 DOI: 10.18632/Oncotarget.12086 |
0.441 |
|
| 2016 |
Rhee H, Ng KL, Tse BW, Yeh MC, Russell PJ, Nelson C, Thomas P, Samaratunga H, Vela I, Gobe G, Wood S. Using prostate specific membrane antigen (PSMA) expression in clear cell renal cell carcinoma for imaging advanced disease. Pathology. PMID 27567227 DOI: 10.1016/J.Pathol.2016.05.011 |
0.429 |
|
| 2016 |
Soekmadji C, Riches JD, Russell PJ, Ruelcke JE, McPherson S, Wang C, Hovens CM, Corcoran NM, The Australian Prostate Cancer Collaboration BioResource, Hill MM, Nelson CC. Modulation of paracrine signaling by CD9 positive small extracellular vesicles mediates cellular growth of androgen deprived prostate cancer. Oncotarget. PMID 27521215 DOI: 10.18632/oncotarget.11111 |
0.382 |
|
| 2016 |
Rhee H, Thomas P, Shepherd B, Greenslade S, Vela I, Russell PJ, Nelson C, Chung E, Wood G, Malone G, Wood S, Heathcote P. PSMA PET May Improve the Diagnostic Accuracy of mpMRI in Localised Prostate Cancer as Confirmed by Whole-Mount Histopathology. The Journal of Urology. PMID 27220897 DOI: 10.1016/J.Juro.2016.02.3000 |
0.513 |
|
| 2016 |
Shah ET, Upadhyaya A, Philp LK, Tang T, Skalamera D, Gunter J, Nelson CC, Williams ED, Hollier BG. Repositioning "old" drugs for new causes: identifying new inhibitors of prostate cancer cell migration and invasion. Clinical & Experimental Metastasis. PMID 26932199 DOI: 10.1007/s10585-016-9785-y |
0.342 |
|
| 2016 |
Rhee H, Gunter J, Javanovic L, Williams E, Hollier B, Nelson C, Vela I. 1064 Delivery of precision medicine in advanced prostate cancer using circulating tumour cells European Urology Supplements. 15. DOI: 10.1016/S1569-9056(16)61065-5 |
0.562 |
|
| 2016 |
Rhee H, Thomas P, Shepherd B, Greenslade S, Vela I, Russell P, Nelson C, Chung E, Wood G, Malone G, Wood S, Heathcote P. 568 PSMA pet improves diagnostic accuracy of mpMRI in localised prostate cancer as confirmed by whole mount histopathology: Implications for selection and assessment for active surveillance and focal therapy European Urology Supplements. 15: e568-e568a. DOI: 10.1016/S1569-9056(16)60570-5 |
0.504 |
|
| 2016 |
Rhee H, Gunter J, Jovanovic L, Williams E, Hollier B, Nelson C, Vela I. MP07-18 PERSISTENCE OF CIRCULATING TUMOUR CELLS (CTCS) IN MEN TREATED WITH ANDROGEN DEPRIVATION THERAPY CAN BE USED TO ENRICH AND PROPAGATE TEMPORARY PERSONALIZED CELL LINES Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.2221 |
0.369 |
|
| 2015 |
Liberio MS, Sadowski MC, Davis RA, Rockstroh A, Vasireddy R, Lehman ML, Nelson CC. The ascidian natural product eusynstyelamide B is a novel topoisomerase II poison that induces DNA damage and growth arrest in prostate and breast cancer cells. Oncotarget. 6: 43944-63. PMID 26733491 DOI: 10.18632/oncotarget.6267 |
0.329 |
|
| 2015 |
Tang KD, Liu J, Jovanovic L, An J, Hill MM, Vela I, Lee TK, Ma S, Nelson C, Russell PJ, Clements JA, Ling MT. Adipocytes promote prostate cancer stem cell self-renewal through amplification of the cholecystokinin autocrine loop. Oncotarget. PMID 26700819 DOI: 10.18632/Oncotarget.6643 |
0.576 |
|
| 2015 |
Schmidt H, Kulasinghe A, Perry C, Nelson C, Punyadeera C. A liquid biopsy for head and neck cancers. Expert Review of Molecular Diagnostics. PMID 26631411 DOI: 10.1586/14737159.2016.1127758 |
0.352 |
|
| 2015 |
Lai J, An J, Seim I, Walpole C, Hoffman A, Moya L, Srinivasan S, Perry-Keene JL, Wang C, Lehman ML, Nelson CC, Clements JA, Batra J. Fusion transcript loci share many genomic features with non-fusion loci. Bmc Genomics. 16: 1021. PMID 26626734 DOI: 10.1186/s12864-015-2235-4 |
0.303 |
|
| 2015 |
Khamenehfar A, Beischlag TV, Russell PJ, Ling MT, Nelson C, Li PC. Label-free isolation of a prostate cancer cell among blood cells and the single-cell measurement of drug accumulation using an integrated microfluidic chip. Biomicrofluidics. 9: 064104. PMID 26594265 DOI: 10.1063/1.4934715 |
0.422 |
|
| 2015 |
Soekmadji C, Nelson CC. The Emerging Role of Extracellular Vesicle-Mediated Drug Resistance in Cancers: Implications in Advanced Prostate Cancer. Biomed Research International. 2015: 454837. PMID 26587537 DOI: 10.1155/2015/454837 |
0.411 |
|
| 2015 |
Gasch C, Plummer PN, Jovanovic L, McInnes LM, Wescott D, Saunders CM, Schneeweiss A, Wallwiener M, Nelson C, Spring KJ, Riethdorf S, Thompson EW, Pantel K, Mellick AS. Heterogeneity of miR-10b expression in circulating tumor cells. Scientific Reports. 5: 15980. PMID 26522916 DOI: 10.1038/Srep15980 |
0.365 |
|
| 2015 |
Tevz G, McGrath S, Demeter R, Magrini V, Jeet V, Rockstroh A, McPherson S, Lai J, Bartonicek N, An J, Batra J, Dinger ME, Lehman ML, Williams ED, Nelson CC. Identification of a novel fusion transcript between human relaxin-1 (RLN1) and human relaxin-2 (RLN2) in prostate cancer. Molecular and Cellular Endocrinology. PMID 26499396 DOI: 10.1016/j.mce.2015.10.011 |
0.476 |
|
| 2015 |
Mertens-Walker I, Fernandini BC, Maharaj MS, Rockstroh A, Nelson CC, Herington AC, Stephenson SA. The tumour-promoting receptor tyrosine kinase, EphB4, regulates expression of integrin-β8 in prostate cancer cells. Bmc Cancer. 15: 164. PMID 25886373 DOI: 10.1186/s12885-015-1164-6 |
0.412 |
|
| 2015 |
Stuchbery R, Kurganovs NJ, McCoy PJ, Nelson CC, Hayes VM, Corcoran NM, Hovens CM. Target acquired: progress and promise of targeted therapeutics in the treatment of prostate cancer. Current Cancer Drug Targets. PMID 25882061 |
0.386 |
|
| 2015 |
Kumar R, Sadowski MC, Levrier C, Nelson CC, Jones AJ, Holleran JP, Avery VM, Healy PC, Davis RA. Design and Synthesis of a Screening Library Using the Natural Product Scaffold 3-Chloro-4-hydroxyphenylacetic Acid. Journal of Natural Products. 78: 914-8. PMID 25803573 DOI: 10.1021/np500856u |
0.316 |
|
| 2015 |
Wang Q, Hardie RA, Hoy AJ, van Geldermalsen M, Gao D, Fazli L, Sadowski MC, Balaban S, Schreuder M, Nagarajah R, Wong JJ, Metierre C, Pinello N, Otte NJ, Lehman ML, ... ... Nelson CC, et al. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development. The Journal of Pathology. 236: 278-89. PMID 25693838 DOI: 10.1002/path.4518 |
0.456 |
|
| 2015 |
Doll A, Clark J, Nelson C. Biomarker and translational prostate cancer research. Biomed Research International. 2015: 309851. PMID 25664317 DOI: 10.1155/2015/309851 |
0.573 |
|
| 2015 |
Rhee H, Gunter JH, Heathcote P, Ho K, Stricker P, Corcoran NM, Nelson CC. Adverse effects of androgen-deprivation therapy in prostate cancer and their management. Bju International. 115: 3-13. PMID 25327530 DOI: 10.1111/bju.12964 |
0.365 |
|
| 2015 |
Kulasinghe A, Perry C, Jovanovic L, Nelson C, Punyadeera C. Circulating tumour cells in metastatic head and neck cancers. International Journal of Cancer. Journal International Du Cancer. 136: 2515-23. PMID 25111594 DOI: 10.1002/Ijc.29108 |
0.399 |
|
| 2015 |
Kulasinghe A, Perry C, Boyle GM, O'Byrne K, Davies A, Jovanovic L, Nelson C, Punyadeera C. Epithelial-mesenchymal axis in head and neck cancer cell lines Journal of Solid Tumors. 6. DOI: 10.5430/Jst.V6N1P28 |
0.314 |
|
| 2014 |
Nouri M, Ratther E, Stylianou N, Nelson CC, Hollier BG, Williams ED. Androgen-targeted therapy-induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: an opportunity for intervention. Frontiers in Oncology. 4: 370. PMID 25566507 DOI: 10.3389/fonc.2014.00370 |
0.508 |
|
| 2014 |
Liberio MS, Sadowski MC, Soekmadji C, Davis RA, Nelson CC. Differential effects of tissue culture coating substrates on prostate cancer cell adherence, morphology and behavior. Plos One. 9: e112122. PMID 25375165 DOI: 10.1371/Journal.Pone.0112122 |
0.425 |
|
| 2014 |
Sadowski MC, Pouwer RH, Gunter JH, Lubik AA, Quinn RJ, Nelson CC. The fatty acid synthase inhibitor triclosan: repurposing an anti-microbial agent for targeting prostate cancer. Oncotarget. 5: 9362-81. PMID 25313139 |
0.392 |
|
| 2014 |
White-Al Habeeb NM, Ho LT, Olkhov-Mitsel E, Kron K, Pethe V, Lehman M, Jovanovic L, Fleshner N, van der Kwast T, Nelson CC, Bapat B. Integrated analysis of epigenomic and genomic changes by DNA methylation dependent mechanisms provides potential novel biomarkers for prostate cancer. Oncotarget. 5: 7858-69. PMID 25277202 DOI: 10.18632/Oncotarget.2313 |
0.308 |
|
| 2014 |
Tse BW, Jovanovic L, Nelson CC, de Souza P, Power CA, Russell PJ. From bench to bedside: immunotherapy for prostate cancer. Biomed Research International. 2014: 981434. PMID 25276838 DOI: 10.1155/2014/981434 |
0.451 |
|
| 2014 |
Lai J, An J, Nelson CC, Lehman ML, Batra J, Clements JA. Analysis of androgen and anti-androgen regulation of KLK-related peptidase 2, 3, and 4 alternative transcripts in prostate cancer. Biological Chemistry. 395: 1127-32. PMID 25153393 DOI: 10.1515/hsz-2014-0149 |
0.519 |
|
| 2014 |
Loh J, Jovanovic L, Lehman M, Capp A, Pryor D, Harris M, Nelson C, Martin J. Circulating tumor cell detection in high-risk non-metastatic prostate cancer. Journal of Cancer Research and Clinical Oncology. 140: 2157-62. PMID 25028119 DOI: 10.1007/S00432-014-1775-3 |
0.512 |
|
| 2014 |
Jeet V, Tevz G, Lehman M, Hollier B, Nelson C. Elevated YKL40 is associated with advanced prostate cancer (PCa) and positively regulates invasion and migration of PCa cells. Endocrine-Related Cancer. 21: 723-37. PMID 24981110 DOI: 10.1530/Erc-14-0267 |
0.575 |
|
| 2014 |
Sieh S, Taubenberger AV, Lehman ML, Clements JA, Nelson CC, Hutmacher DW. Paracrine interactions between LNCaP prostate cancer cells and bioengineered bone in 3D in vitro culture reflect molecular changes during bone metastasis. Bone. 63: 121-31. PMID 24530694 DOI: 10.1016/j.bone.2014.02.001 |
0.401 |
|
| 2014 |
Vela I, Morrissey C, Zhang X, Chen S, Corey E, Strutton GM, Nelson CC, Nicol DL, Clements JA, Gardiner EM. PITX2 and non-canonical Wnt pathway interaction in metastatic prostate cancer. Clinical & Experimental Metastasis. 31: 199-211. PMID 24162257 DOI: 10.1007/S10585-013-9620-7 |
0.576 |
|
| 2013 |
Soekmadji C, Russell PJ, Nelson CC. Exosomes in prostate cancer: putting together the pieces of a puzzle. Cancers. 5: 1522-44. PMID 24351670 DOI: 10.3390/cancers5041522 |
0.448 |
|
| 2013 |
Wang Q, Tiffen J, Bailey CG, Lehman ML, Ritchie W, Fazli L, Metierre C, Feng YJ, Li E, Gleave M, Buchanan G, Nelson CC, Rasko JE, Holst J. Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development. Journal of the National Cancer Institute. 105: 1463-73. PMID 24052624 DOI: 10.1093/jnci/djt241 |
0.35 |
|
| 2013 |
Baron PS, Neve JE, Camp D, Suraweera L, Lam A, Lai J, Jovanovic L, Nelson C, Davis RA. Design, synthesis and spectroscopic characterisation of a focused library based on the polyandrocarpamine natural product scaffold. Magnetic Resonance in Chemistry : Mrc. 51: 358-63. PMID 23609961 DOI: 10.1002/Mrc.3958 |
0.344 |
|
| 2013 |
Gunter JH, Sarkar PL, Lubik AA, Nelson CC. New players for advanced prostate cancer and the rationalisation of insulin-sensitising medication. International Journal of Cell Biology. 2013: 834684. PMID 23573093 DOI: 10.1155/2013/834684 |
0.536 |
|
| 2013 |
Lubik AA, Gunter JH, Hollier BG, Ettinger S, Fazli L, Stylianou N, Hendy SC, Adomat HH, Gleave ME, Pollak M, Herington A, Nelson CC. IGF2 increases de novo steroidogenesis in prostate cancer cells. Endocrine-Related Cancer. 20: 173-86. PMID 23319492 DOI: 10.1530/Erc-12-0250 |
0.359 |
|
| 2013 |
Seim I, Lubik AA, Lehman ML, Tomlinson N, Whiteside EJ, Herington AC, Nelson CC, Chopin LK. Cloning of a novel insulin-regulated ghrelin transcript in prostate cancer. Journal of Molecular Endocrinology. 50: 179-91. PMID 23267039 DOI: 10.1530/JME-12-0150 |
0.429 |
|
| 2013 |
Sieh S, Taubenberger AV, Rizzi SC, Sadowski M, Lehman ML, Rockstroh A, An J, Clements JA, Nelson CC, Hutmacher DW. Correction: Phenotypic Characterization of Prostate Cancer LNCaP Cells Cultured within a Bioengineered Microenvironment Plos One. 8. DOI: 10.1371/annotation/a26f1a2e-2765-4c10-942e-d2a738b80bf9 |
0.471 |
|
| 2013 |
Ziaee S, Sieh S, Chu C, Wang R, Hutmacher DW, Nelson C, Guo C, Chung LWK. Abstract B11: Using three-dimensional (3-D) culture systems to delineate the role of RANKL in metastatic prostate cancer Cancer Research. 73: 4997-4997. DOI: 10.1158/1538-7445.Tim2013-B11 |
0.439 |
|
| 2013 |
Ziaee S, Sieh S, Chu GC, Wang R, Hutmacher D, Nelson C, Guo C, Chung LW. 500 USING THREE-DIMENSIONAL (3D) CULTURE SYSTEMS TO DELINEATE THE ROLE OF RANKL IN METASTATIC PROSTATE CANCER Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.1894 |
0.464 |
|
| 2013 |
Lehman ML, Nelson CC. Toward revealing the complexity of androgen-responsive protein and noncoding transcripts in prostate cancer Androgen-Responsive Genes in Prostate Cancer: Regulation, Function and Clinical Applications. 2147483647: 117-134. DOI: 10.1007/978-1-4614-6182-1_8 |
0.464 |
|
| 2012 |
Wang C, Taciroglu A, Maetschke SR, Nelson CC, Ragan MA, Davis MJ. mCOPA: analysis of heterogeneous features in cancer expression data. Journal of Clinical Bioinformatics. 2: 22. PMID 23216803 DOI: 10.1111/Bju.12293 |
0.483 |
|
| 2012 |
Wagholikar A, Fung M, Nelson C. Improving self-care of patients with chronic disease using online personal health record. The Australasian Medical Journal. 5: 517-21. PMID 23115588 DOI: 10.4066/Amj.2012.1358 |
0.39 |
|
| 2012 |
Uemura H, Nelson C, Schalken JA, Klotz L. Personalized cancer therapy for urological cancers: from bench to bedside and back. Advances in Urology. 2012: 298105. PMID 23008703 DOI: 10.1155/2012/298105 |
0.529 |
|
| 2012 |
Sieh S, Taubenberger AV, Rizzi SC, Sadowski M, Lehman ML, Rockstroh A, An J, Clements JA, Nelson CC, Hutmacher DW. Phenotypic characterization of prostate cancer LNCaP cells cultured within a bioengineered microenvironment. Plos One. 7: e40217. PMID 22957009 DOI: 10.1371/journal.pone.0040217 |
0.476 |
|
| 2012 |
Gunter JH, Lubik AA, McKenzie I, Pollak M, Nelson CC. The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer. Advances in Urology. 2012: 248607. PMID 22548055 DOI: 10.1155/2012/248607 |
0.457 |
|
| 2012 |
Thompson VC, Day TK, Bianco-Miotto T, Selth LA, Han G, Thomas M, Buchanan G, Scher HI, Nelson CC, Greenberg NM, Butler LM, Tilley WD. A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease. International Journal of Cancer. Journal International Du Cancer. 131: 662-72. PMID 22275114 DOI: 10.1002/ijc.26414 |
0.533 |
|
| 2012 |
Wang Q, Bailey CG, Ng C, Tiffen J, Thoeng A, Minnas V, Lehman ML, Hendy SC, Buchanan G, Nelson CC, Rasko JE, Holst J. Androgen receptor and nutrient signaling pathways coordinate increased amino acid transport in prostate cancer progression Bmc Proceedings. 6. DOI: 10.1186/1753-6561-6-S3-P23 |
0.383 |
|
| 2012 |
Lubik A, Gunter J, Ettinger S, Fazil L, Stylianou N, Hendy S, Adomat H, Hollier B, Gleave M, Pollak M, Herington A, Nelson C. P03-26 Insulin-like Growth Factor-II increases de novo steroidogenesis in prostate cancer cells Growth Hormone & Igf Research. 22: S80. DOI: 10.1016/S1096-6374(12)60211-1 |
0.389 |
|
| 2011 |
Wang Q, Bailey CG, Ng C, Tiffen J, Thoeng A, Minhas V, Lehman ML, Hendy SC, Buchanan G, Nelson CC, Rasko JE, Holst J. Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression. Cancer Research. 71: 7525-36. PMID 22007000 DOI: 10.1158/0008-5472.CAN-11-1821 |
0.421 |
|
| 2011 |
Shiota M, Zoubeidi A, Kumano M, Beraldi E, Naito S, Nelson CC, Sorensen PH, Gleave ME. Clusterin is a critical downstream mediator of stress-induced YB-1 transactivation in prostate cancer. Molecular Cancer Research : McR. 9: 1755-66. PMID 21987172 DOI: 10.1016/J.Juro.2012.02.550 |
0.516 |
|
| 2011 |
Wagholikar A, Fung M, Nelson C. A pilot study on understanding the journey of advanced prostate cancer patients. Studies in Health Technology and Informatics. 168: 165-71. PMID 21893925 |
0.447 |
|
| 2011 |
Lubik AA, Gunter JH, Hendy SC, Locke JA, Adomat HH, Thompson V, Herington A, Gleave ME, Pollak M, Nelson CC. Insulin increases de novo steroidogenesis in prostate cancer cells. Cancer Research. 71: 5754-64. PMID 21747118 DOI: 10.1158/0008-5472.Can-10-2470 |
0.426 |
|
| 2011 |
Luk SU, Yap WN, Chiu YT, Lee DT, Ma S, Lee TK, Vasireddy RS, Wong YC, Ching YP, Nelson C, Yap YL, Ling MT. Gamma-tocotrienol as an effective agent in targeting prostate cancer stem cell-like population. International Journal of Cancer. Journal International Du Cancer. 128: 2182-91. PMID 20617516 DOI: 10.1002/Ijc.25546 |
0.554 |
|
| 2010 |
Sieh S, Lubik AA, Clements JA, Nelson CC, Hutmacher DW. Interactions between human osteoblasts and prostate cancer cells in a novel 3D in vitro model Organogenesis. 6: 181-188. PMID 21197221 DOI: 10.4161/org.6.3.12041 |
0.437 |
|
| 2010 |
Mostaghel E, Nelson PS, Nelson C, Montgomery RB. Intraprostatic steroidogenic enzymes - letter. Cancer Research. 70: 8247-9; author reply. PMID 20940409 DOI: 10.1158/0008-5472.Can-10-1458 |
0.496 |
|
| 2010 |
Haddad AQ, Fleshner N, Nelson C, Saour B, Musquera M, Venkateswaran V, Klotz L. Antiproliferative mechanisms of the flavonoids 2,2'-dihydroxychalcone and fisetin in human prostate cancer cells. Nutrition and Cancer. 62: 668-81. PMID 20574928 DOI: 10.1080/01635581003605524 |
0.512 |
|
| 2010 |
Thompson VC, Hurtado-Coll A, Turbin D, Fazli L, Lehman ML, Gleave ME, Nelson CC. Relaxin drives Wnt signaling through upregulation of PCDHY in prostate cancer. The Prostate. 70: 1134-45. PMID 20503398 DOI: 10.1002/pros.21148 |
0.463 |
|
| 2010 |
Lai J, Lehman ML, Dinger ME, Hendy SC, Mercer TR, Seim I, Lawrence MG, Mattick JS, Clements JA, Nelson CC. A variant of the KLK4 gene is expressed as a cis sense-antisense chimeric transcript in prostate cancer cells. Rna (New York, N.Y.). 16: 1156-66. PMID 20406994 DOI: 10.1261/rna.2019810 |
0.44 |
|
| 2010 |
Andrieu C, Taieb D, Baylot V, Ettinger S, Soubeyran P, De-Thonel A, Nelson C, Garrido C, So A, Fazli L, Bladou F, Gleave M, Iovanna JL, Rocchi P. Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E. Oncogene. 29: 1883-1896. PMID 20101233 DOI: 10.1038/Onc.2009.479 |
0.508 |
|
| 2010 |
Zoubeidi A, Ettinger S, Beraldi E, Hadaschik B, Zardan A, Klomp LW, Nelson CC, Rennie PS, Gleave ME. Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity in prostate cancer cells. Molecular Cancer Research : McR. 8: 119-30. PMID 20068069 DOI: 10.1158/1541-7786.Mcr-09-0277 |
0.464 |
|
| 2010 |
Leon CG, Locke JA, Adomat HH, Etinger SL, Twiddy AL, Neumann RD, Nelson CC, Guns ES, Wasan KM. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. The Prostate. 70: 390-400. PMID 19866465 DOI: 10.1002/Pros.21072 |
0.401 |
|
| 2010 |
Locke JA, Guns ES, Lehman ML, Ettinger S, Zoubeidi A, Lubik A, Margiotti K, Fazli L, Adomat H, Wasan KM, Gleave ME, Nelson CC. Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance. The Prostate. 70: 239-51. PMID 19790237 DOI: 10.1002/Pros.21057 |
0.443 |
|
| 2010 |
Vela I, Morrissey C, Corey E, Vessella R, Chen S, Strutton G, Nelson C, Clements J, Nicol D, Gardiner EM. Prostate cancer metastasis, the noncanonical Wnt pathway, and the transcription factor PITX2. Journal of Clinical Oncology. 28: 4647-4647. DOI: 10.1200/Jco.2010.28.15_Suppl.4647 |
0.553 |
|
| 2010 |
Vela I, Morrissey C, Corey E, Vessella R, Chen S, Strutton G, Nelson C, Clements J, Nicol D, Gardiner E. 554 INCREMENTAL EXPRESSION OF PITX2, A WNT PATHWAY ASSOCIATED TRANSCRIPTION FACTOR IN PRIMARY AND METASTATIC PROSTATE CANCER Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.774 |
0.549 |
|
| 2009 |
Yi Y, Nandana S, Case T, Nelson C, Radmilovic T, Matusik RJ, Tsuchiya KD. Candidate metastasis suppressor genes uncovered by array comparative genomic hybridization in a mouse allograft model of prostate cancer. Molecular Cytogenetics. 2: 18. PMID 19781100 DOI: 10.1186/1755-8166-2-18 |
0.472 |
|
| 2009 |
Locke JA, Nelson CC, Adomat HH, Hendy SC, Gleave ME, Guns ES. Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts. The Journal of Steroid Biochemistry and Molecular Biology. 115: 126-36. PMID 19442514 DOI: 10.1016/j.jsbmb.2009.03.011 |
0.426 |
|
| 2009 |
Locke JA, Fazli L, Adomat H, Smyl J, Weins K, Lubik AA, Hales DB, Nelson CC, Gleave ME, Tomlinson Guns ES. A novel communication role for CYP17A1 in the progression of castration-resistant prostate cancer. The Prostate. 69: 928-37. PMID 19267349 DOI: 10.1002/Pros.20940 |
0.465 |
|
| 2009 |
Snoek R, Cheng H, Margiotti K, Wafa LA, Wong CA, Wong EC, Fazli L, Nelson CC, Gleave ME, Rennie PS. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 39-47. PMID 19118031 DOI: 10.1158/1078-0432.Ccr-08-1726 |
0.399 |
|
| 2009 |
Telesca D, Inoue LY, Neira M, Etzioni R, Gleave M, Nelson C. Differential expression and network inferences through functional data modeling. Biometrics. 65: 793-804. PMID 19053995 DOI: 10.1111/J.1541-0420.2008.01159.X |
0.352 |
|
| 2008 |
Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Research. 68: 6407-15. PMID 18676866 DOI: 10.1158/0008-5472.CAN-07-5997 |
0.473 |
|
| 2008 |
Sanderson T, Renaud M, Scholten D, Nijmeijer S, van den Berg M, Cowell S, Guns E, Nelson C, Mutarapat T, Ruchirawat S. Effects of lactone derivatives on aromatase (CYP19) activity in H295R human adrenocortical and (anti)androgenicity in transfected LNCaP human prostate cancer cells. European Journal of Pharmacology. 593: 92-8. PMID 18639541 DOI: 10.1016/J.Ejphar.2008.06.085 |
0.453 |
|
| 2008 |
Locke JA, Wasan KM, Nelson CC, Guns ES, Leon CG. Androgen-mediated cholesterol metabolism in LNCaP and PC-3 cell lines is regulated through two different isoforms of acyl-coenzyme A:Cholesterol Acyltransferase (ACAT). The Prostate. 68: 20-33. PMID 18000807 DOI: 10.1002/Pros.20674 |
0.4 |
|
| 2008 |
Vela I, Gregory L, Nelson CC, Clements JA, Gardiner EM, Nicol DL. KALLIKREIN RELATED PROTEASES AND WNT PATHWAY INTERACTIONS IN PROSTATE CANCER Journal of Urology. 179: 424-425. DOI: 10.1016/S0022-5347(08)61245-8 |
0.44 |
|
| 2007 |
Zoubeidi A, Zardan A, Beraldi E, Fazli L, Sowery R, Rennie P, Nelson C, Gleave M. Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Research. 67: 10455-65. PMID 17974989 DOI: 10.1158/0008-5472.Can-07-2057 |
0.518 |
|
| 2007 |
Margiotti K, Wafa LA, Cheng H, Novelli G, Nelson CC, Rennie PS. Androgen-regulated genes differentially modulated by the androgen receptor coactivator L-dopa decarboxylase in human prostate cancer cells. Molecular Cancer. 6: 38. PMID 17553164 DOI: 10.1186/1476-4598-6-38 |
0.539 |
|
| 2007 |
Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM, Bremner WJ, Gleave ME, Nelson PS. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Research. 67: 5033-41. PMID 17510436 DOI: 10.1158/0008-5472.Can-06-3332 |
0.529 |
|
| 2007 |
Cochrane DR, Wang Z, Muramaki M, Gleave ME, Nelson CC. Differential regulation of clusterin and its isoforms by androgens in prostate cells. The Journal of Biological Chemistry. 282: 2278-87. PMID 17148459 DOI: 10.1074/jbc.M608162200 |
0.488 |
|
| 2007 |
Wafa LA, Palmer J, Fazli L, Hurtado-Coll A, Bell RH, Nelson CC, Gleave ME, Cox ME, Rennie PS. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors. Human Pathology. 38: 161-70. PMID 16997353 DOI: 10.1016/J.Humpath.2006.07.003 |
0.512 |
|
| 2007 |
Inoue LY, Neira M, Nelson C, Gleave M, Etzioni R. Cluster-based network model for time-course gene expression data. Biostatistics (Oxford, England). 8: 507-25. PMID 16980695 DOI: 10.1093/Biostatistics/Kxl026 |
0.33 |
|
| 2007 |
Muramaki M, Nelson C, Miyake H, Fujisawa M, Gleave ME. 1137: Antisense Inhibition of Clusterin Enhances Apoptotic Cell Death in Human Prostate Cancer Cells through not Only Down-Regulation of Anti-Apoptotic Clusterin Isoform but Up-Regulation of Pro-Apoptotic Clusterin Isoform Journal of Urology. 177: 375-375. DOI: 10.1016/S0022-5347(18)31351-X |
0.503 |
|
| 2006 |
Thompson VC, Morris TG, Cochrane DR, Cavanagh J, Wafa LA, Hamilton T, Wang S, Fazli L, Gleave ME, Nelson CC. Relaxin becomes upregulated during prostate cancer progression to androgen independence and is negatively regulated by androgens. The Prostate. 66: 1698-709. PMID 16998820 DOI: 10.1002/pros.20423 |
0.508 |
|
| 2006 |
Rocchi P, Jugpal P, So A, Sinneman S, Ettinger S, Fazli L, Nelson C, Gleave M. Small interference RNA targeting heat-shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in vitro. Bju International. 98: 1082-9. PMID 16879439 DOI: 10.1111/J.1464-410X.2006.06425.X |
0.547 |
|
| 2006 |
Kojima S, Mulholland DJ, Ettinger S, Fazli L, Nelson CC, Gleave ME. Differential regulation of IGFBP-3 by the androgen receptor in the lineage-related androgen-dependent LNCaP and androgen-independent C4-2 prostate cancer models. The Prostate. 66: 971-86. PMID 16541420 DOI: 10.1002/pros.20420 |
0.469 |
|
| 2006 |
Mulholland DJ, Dedhar S, Wu H, Nelson CC. PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. Oncogene. 25: 329-37. PMID 16421604 DOI: 10.1038/Sj.Onc.1209020 |
0.492 |
|
| 2006 |
Yu D, Scott C, Jia WW, De Benedetti A, Williams BJ, Fazli L, Wen Y, Gleave M, Nelson C, Rennie PS. Targeting and killing of prostate cancer cells using lentiviral constructs containing a sequence recognized by translation factor eIF4E and a prostate-specific promoter. Cancer Gene Therapy. 13: 32-43. PMID 16052226 DOI: 10.1038/Sj.Cgt.7700885 |
0.569 |
|
| 2005 |
Eigl BJ, Baybik J, Ettinger S, Chi KN, Nelson C, Gleave ME. Preclinical evidence that chemotherapy for prostate cancer should be given at the same time as androgen withdrawal. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4617. PMID 27946992 DOI: 10.1200/Jco.2005.23.16_Suppl.4617 |
0.529 |
|
| 2005 |
Rocchi P, Beraldi E, Ettinger S, Fazli L, Vessella RL, Nelson C, Gleave M. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Research. 65: 11083-93. PMID 16322258 DOI: 10.1158/0008-5472.Can-05-1840 |
0.571 |
|
| 2005 |
Eigl BJ, Eggener SE, Baybik J, Ettinger S, Chi KN, Nelson C, Wang Z, Gleave ME. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 4905-11. PMID 16000589 DOI: 10.1158/1078-0432.Ccr-04-2140 |
0.506 |
|
| 2005 |
Figueiredo KA, Palmer JB, Mui AL, Nelson CC, Cox ME. Demonstration of upregulated H2 relaxin mRNA expression during neuroendocrine differentiation of LNCaP prostate cancer cells and production of biologically active mammalian recombinant 6 histidine-tagged H2 relaxin Annals of the New York Academy of Sciences. 1041: 320-327. PMID 15956728 DOI: 10.1196/annals.1282.051 |
0.489 |
|
| 2005 |
Zhou Y, Dai DL, Martinka M, Su M, Zhang Y, Campos EI, Dorocicz I, Tang L, Huntsman D, Nelson C, Ho V, Li G. Osteopontin expression correlates with melanoma invasion. The Journal of Investigative Dermatology. 124: 1044-52. PMID 15854047 DOI: 10.1111/J.0022-202X.2005.23680.X |
0.363 |
|
| 2005 |
Sutherland BW, Kucab J, Wu J, Lee C, Cheang MC, Yorida E, Turbin D, Dedhar S, Nelson C, Pollak M, Leighton Grimes H, Miller K, Badve S, Huntsman D, Blake-Gilks C, et al. Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene. 24: 4281-92. PMID 15806160 DOI: 10.1038/Sj.Onc.1208590 |
0.362 |
|
| 2005 |
So A, Gleave M, Hurtado-Col A, Nelson C. Mechanisms of the development of androgen independence in prostate cancer. World Journal of Urology. 23: 1-9. PMID 15770516 DOI: 10.1007/S00345-004-0473-1 |
0.593 |
|
| 2005 |
Kojima S, Mulholland DJ, Nelson CC, Gleave ME. 572: Differential Regulation of IGFBP-3 by the Androgen Receptor in Progression to Androgen Independent Prostate Cancer Journal of Urology. 173: 156-156. DOI: 10.1016/s0022-5347(18)34812-2 |
0.486 |
|
| 2004 |
Yu D, Jia WW, Gleave ME, Nelson CC, Rennie PS. Prostate-tumor targeting of gene expression by lentiviral vectors containing elements of the probasin promoter. The Prostate. 59: 370-82. PMID 15065085 DOI: 10.1002/Pros.20010 |
0.443 |
|
| 2004 |
Mulholland DJ, Cox M, Read J, Rennie P, Nelson C. Androgen responsiveness of Renilla luciferase reporter vectors is promoter, transgene, and cell line dependent. The Prostate. 59: 115-9. PMID 15042611 DOI: 10.1002/Pros.20059 |
0.471 |
|
| 2004 |
Giménez-Bonafé P, Fedoruk MN, Whitmore TG, Akbari M, Ralph JL, Ettinger S, Gleave ME, Nelson CC. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. The Prostate. 59: 337-49. PMID 15042610 DOI: 10.1002/Pros.20023 |
0.749 |
|
| 2004 |
Ettinger SL, Sobel R, Whitmore TG, Akbari M, Bradley DR, Gleave ME, Nelson CC. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Research. 64: 2212-21. PMID 15026365 DOI: 10.1158/0008-5472.CAN-2148-2 |
0.522 |
|
| 2004 |
Fedoruk MN, Giménez-Bonafé P, Guns ES, Mayer LD, Nelson CC. P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells. The Prostate. 59: 77-90. PMID 14991868 DOI: 10.1002/pros.10354 |
0.423 |
|
| 2004 |
Zhang J, Gao N, Kasper S, Reid K, Nelson C, Matusik RJ. An androgen-dependent upstream enhancer is essential for high levels of probasin gene expression. Endocrinology. 145: 134-48. PMID 14500578 DOI: 10.1210/En.2003-0568 |
0.463 |
|
| 2003 |
Mulholland DJ, Read JT, Rennie PS, Cox ME, Nelson CC. Functional localization and competition between the androgen receptor and T-cell factor for nuclear β-catenin: A means for inhibition of the Tcf signaling axis Oncogene. 22: 5602-5613. PMID 12944908 DOI: 10.1038/Sj.Onc.1206802 |
0.316 |
|
| 2003 |
Wafa LA, Cheng H, Rao MA, Nelson CC, Cox M, Hirst M, Sadowski I, Rennie PS. Isolation and identification of L-dopa decarboxylase as a protein that binds to and enhances transcriptional activity of the androgen receptor using the repressed transactivator yeast two-hybrid system. The Biochemical Journal. 375: 373-83. PMID 12864730 DOI: 10.1042/Bj20030689 |
0.32 |
|
| 2003 |
Nelson CC, Hoffart D, Gleave ME, Rennie PS. Application of gene microarrays in the study of prostate cancer. Methods in Molecular Medicine. 81: 299-320. PMID 12725128 DOI: 10.1385/1-59259-372-0:299 |
0.481 |
|
| 2003 |
Ralph JL, Orgebin-Crist MC, Lareyre JJ, Nelson CC. Disruption of androgen regulation in the prostate by the environmental contaminant hexachlorobenzene. Environmental Health Perspectives. 111: 461-6. PMID 12676599 DOI: 10.1289/Ehp.5919 |
0.734 |
|
| 2003 |
Gleave M, Nelson C, Chi K. Antisense targets to enhance hormone and cytotoxic therapies in advanced prostate cancer. Current Drug Targets. 4: 209-21. PMID 12643471 DOI: 10.2174/1389450033491190 |
0.544 |
|
| 2003 |
Yeung LH, Read JT, Sorenson P, Nelson CC, Jia W, Rennie PS. Identification and characterization of a prostate-specific androgen-independent protein-binding site in the probasin promoter. The Biochemical Journal. 371: 843-55. PMID 12540291 DOI: 10.1042/Bj20021816 |
0.486 |
|
| 2001 |
Gleave ME, Miyake H, Zellweger T, Chi K, July L, Nelson C, Rennie P. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. Urology. 58: 39-49. PMID 11502446 DOI: 10.1016/S0090-4295(01)01241-9 |
0.594 |
|
| 2001 |
Lareyre JJ, Reid K, Nelson C, Kasper S, Rennie PS, Orgebin-Crist MC, Matusik RJ. Characterization of an androgen-specific response region within the 5' flanking region of the murine epididymal retinoic acid binding protein gene. Biology of Reproduction. 63: 1881-92. PMID 11090461 DOI: 10.1095/Biolreprod63.6.1881 |
0.405 |
|
| 2000 |
Miyake H, Nelson C, Rennie PS, Gleave ME. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3'-kinase pathway. Endocrinology. 141: 2257-65. PMID 10830316 DOI: 10.1210/Endo.141.6.7520 |
0.505 |
|
| 2000 |
Gleave ME, Miayake H, Goldie J, Nelson C, Tolcher A. Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides. Urology. 54: 36-46. PMID 10606283 DOI: 10.1016/S0090-4295(99)00453-7 |
0.426 |
|
| 1999 |
Rennie PS, Nelson CC. Epigenetic mechanisms for progression of prostate cancer. Cancer Metastasis Reviews. 17: 401-9. PMID 10453284 DOI: 10.1023/A:1006121219097 |
0.45 |
|
| Show low-probability matches. |